Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: sepsis therapeutics - Hansa Biopharma AB

Drug Profile

Research programme: sepsis therapeutics - Hansa Biopharma AB

Alternative Names: HM-401; HM-402

Latest Information Update: 28 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hansa Medical AB
  • Developer Hansa Biopharma AB
  • Class Peptides
  • Mechanism of Action Bradykinin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sepsis

Most Recent Events

  • 20 Dec 2018 Hasna Medical AB is now Hansa Biomedical AB
  • 09 Dec 2011 Discontinued - Preclinical for Sepsis in Sweden (unspecified route)
  • 19 Feb 2009 Preclinical development is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top